versicolorin A: see also versicolorin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
versicolorin A : An organic heteropentacyclic compound that is 3a,12a-dihydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione carrying three hydroxy substituents at positions 4, 6 and 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 638297 |
CHEBI ID | 72676 |
SCHEMBL ID | 3272235 |
MeSH ID | M0094888 |
Synonym |
---|
4,6,8-trihydroxy-3a,12a-dihydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione |
nsc 274542 |
z-(-)-4,6,8-trihydroxy-3a,12a-dihydroanthra(2,3-b)furo(3,2-d)furan-5,10-dione |
anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 3a,12a-dihydro-4,6,8-trihydroxy-, z-(-)- |
versicolorin a |
ccris 3475 |
CHEBI:72676 |
(3as,12ar)-4,6,8-trihydroxy-3a,12a-dihydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione |
6807-96-1 |
nsc-274542 |
anthra[2,3-b]furo[3,2-d]furan-5,10-dione, 3a,12a-dihydro-4,6,8-trihydroxy-, (3as-cis)- |
unii-du1m9u6126 |
du1m9u6126 , |
C20583 |
SCHEMBL3272235 |
4,6,8-trihydroxy-3a,12a-dihydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione # |
SJNDYXPJRUTLNW-ULCDLSAGSA-N |
(3as,12ar)-3a,12a-dihydro-4,6,8-trihydroxyanthra(2,3-b)furo(3,2-d)furan-5,10-dione |
anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 3a,12a-dihydro-4,6,8-trihydroxy-, (3as,12ar)- |
anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 3a,12a-dihydro-4,6,8-trihydroxy-, (3as-cis)- |
Q27140069 |
(4s,8r)-2,16,18-trihydroxy-7,9-dioxapentacyclo[10.8.0.03,10.04,8.014,19]icosa-1,3(10),5,11,14(19),15,17-heptaene-13,20-dione |
HY-129247 |
CS-0104394 |
anthra[2,3-b]furo[3,2-d]furan-5,10-dione, 3a,12a-dihydro-4,6,8-trihydroxy-, (3as,12ar)- |
AKOS040754350 |
Versicolorin A (VerA) is a precursor of AFB1 biosynthesis and is structurally related to the latter.
Excerpt | Reference | Relevance |
---|---|---|
"Versicolorin A (VerA) is a precursor of AFB1 biosynthesis and is structurally related to the latter." | ( Mutagenicity and genotoxicity assessment of the emerging mycotoxin Versicolorin A, an Aflatoxin B1 precursor. Al-Ayoubi, C; Alonso-Jauregui, M; Azqueta, A; Mirey, G; Oswald, IP; Puel, O; Rocher, O; Soler, L; Vettorazzi, A; Vignard, J, 2023) | 1.87 |
Excerpt | Reference | Relevance |
---|---|---|
"Aflatoxins are a group of mycotoxins that have major adverse effects on human health." | ( Versicolorin A enhances the genotoxicity of aflatoxin B1 in human liver cells by inducing the transactivation of the Ah-receptor. Al-Ayoubi, C; Brouwer, A; Budin, C; Man, HY; Oswald, IP; Puel, S; Soler, L; van der Burg, B; van Vugt-Lussenburg, BMA, 2021) | 2.06 |
Role | Description |
---|---|
carcinogenic agent | A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities. |
Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
cyclic acetal | An acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring. |
organic heteropentacyclic compound | |
polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
p-quinones | A quinone in which the two oxo groups of the quinone are located para to each other on the 6-membered quinonoid ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (28.00) | 18.7374 |
1990's | 4 (16.00) | 18.2507 |
2000's | 4 (16.00) | 29.6817 |
2010's | 5 (20.00) | 24.3611 |
2020's | 5 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.48) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (8.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 23 (92.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |